treatment, the concept of disease remission has become something we can aspire to," said allergist Michael Blaiss, MD, a member of the work group and lead author of the paper."To date, there is no standard, accepted definition for clinical remission on treatment in asthma. We see this document as a jumping-off point, and a template to allow for further clinical research.
The following three criteria were unanimously agreed upon by members of the work group, who said they must be met over a 12-month period, and may be applied to those receiving monoclonal antibody therapy for asthma: The remaining three criteria deal with frequency of use of certain therapies as well as measures of asthma symptoms such as assessment questionnaires and/or tools.